(Q28303010)

2

0 references

Dieter Arbter

3

0 references

Rolf R Engel

4

0 references

Chunbo Li

5

0 references

John M Davis

Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator

6

0 references

language of work or name

English

0 references

publication date

3 January 2009

0 references

published in

The Lancet

0 references

volume

373

0 references

issue

9657

0 references

page(s)

31-41

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

A meta-analysis of the efficacy of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Measuring inconsistency in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

A controlled dose comparison of haloperidol in newly admitted schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Patterns of antipsychotic and anticholinergic prescribing for hospital inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

Perphenazine for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2808%2961764-X

7 January 2021

10.1016/S0140-6736(08)61764-X

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

711027

711027

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference